Beren Therapeutics

Clinical-stage biotech developing adrabetadex for infantile-onset Niemann-Pick disease type C and other disorders of cholesterol trafficking.

View on the globe

$135MEquity raised in 2025–20262025 — · 2026 $135M · 1 equity round
$135MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
$165MDebt financingnot counted as equity · all in 2025–2026

Rounds over time log-scaled amounts

Funding history: 2 rounds from 10 Jun 2026 to 10 Jun 2026, $135M equity disclosed, plus $165M debt or secondary. Earlier rounds exist but are not sourced.10 Jun 2026: Equity financing, $135M; 10 Jun 2026: Hercules Capital debt and royalty financing (debt, not equity), $165M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 20192026Q2Q3Q42027Equity roundDebt / secondary10 Jun 2026 · Hercules Capital debt and royalty financing (debt, not counted as equity) · $165M · led by Hercules Capital10 Jun 2026 · Equity financing · $135MDebt · $165MVenture · $135M
Funding history: 2 rounds from 10 Jun 2026 to 10 Jun 2026, $135M equity disclosed, plus $165M debt or secondary. Earlier rounds exist but are not sourced.10 Jun 2026: Equity financing, $135M; 10 Jun 2026: Hercules Capital debt and royalty financing (debt, not equity), $165M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’192026Q2Q3Q42027Equity roundDebt / secondary10 Jun 2026 · Hercules Capital debt and royalty financing (debt, not counted as equity) · $165M · led by Hercules Capital10 Jun 2026 · Equity financing · $135M$165M debt$135M

Funding history 2 rounds · 3 sources · newest first

Earlier rounds not yet sourced. Beren Therapeutics was founded in 2019 and raised before 10 Jun 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Hercules Capital debt and royalty financingDebt · not equity
    Amount$165M
    Post-money—
    ✓ Confirmed
    Lead
    Hercules Capital
    Note
    Up to $165M non-dilutive: up to $110M milestone-based senior-secured term loans ($30M drawn at close) plus $55M royalty financing funded on FDA approval; a ceiling, not capital received. Not counted as equity.
    Sources
  2. Equity financing
    Amount$135M
    Post-money—
    ✓ Confirmed
    Also
    Wellington Partners, JIC Venture Growth Investments, Founders Fund, Narya Capital, Eisai
    Note
    Equity part of a $300M package announced with Hercules Capital debt and royalty financing (separate entry). No lead named; round label not stated. Earlier rounds are not sourced here.
    Sources
  3. Earlier rounds not yet sourced

Investors 5

  • Eisai
  • Founders Fund
  • JIC Venture Growth Investments
  • Narya Capital
  • Wellington Partners

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Lenders and secondary buyers 1

  • Hercules CapitalDebt · lead

Took part only in debt or secondary rounds, so they are not counted as investors and draw no links on the globe.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Beren Therapeutics and its logo are trademarks of their owners, used here for identification only.